Please watch the On Demand miniWebinar: How AbXtract™ and Deeper Sequencing can Guide your Antibody Lead Selection and Prioritization that was presented by M. Frank Erasmus, MS, PhD, Head of Bioinformatics at Specifica, Inc., on June 16, 2022.
Discovery campaigns come in a variety of options, with many different means to the same end goal: a diverse panel of antibodies with therapeutic potential. We have shown that next-generation sequencing (NGS) provides a more complete overview of the underlying antibody population from in-vitro selections.
However, NGS data analysis presents computational and interpretation challenges, along with no less significant hurdles in data managing and sharing across one’s organization.
In this webinar, we deep dive into how AbXtract™, a module within OpenEye’s Orion®Antibody Discovery Suite, simplifies the handling of NGS datasets and streamlines your selection campaign to identify lead candidates in a more efficient manner.
In this webinar, Dr. Erasmus demonstrates how AbXtract can be used for antibody lead selection and prioritization including:
- Background on NGS and informatics in antibody discovery
- Introduction of AbXtract
- Unsupervised machine learning (ML) to cluster the antibody paratope space
- Correlation of SPR derived kinetics to NGS metrics
- Improvement of binding/non-binding classification & regression models with supervised ML